Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.

Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF
J Immunother. 2009 32 (2): 181-5

PMID: 19238017 · DOI:10.1097/CJI.0b013e3181952b1d

MeSH Terms (24)

Angiogenesis Inhibitors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Benzenesulfonates Bevacizumab Carcinoma, Renal Cell Female Heart Diseases Humans Indoles Interleukin-2 Kidney Neoplasms Male Middle Aged Niacinamide Phenylurea Compounds Pyridines Pyrroles Retrospective Studies Salvage Therapy Sorafenib Sunitinib Vascular Endothelial Growth Factor A

Connections (1)

This publication is referenced by other Labnodes entities: